Photo of Dr Neill Liptrott

Dr Neill Liptrott PhD, FHEA, FRSB

Reader in Pharmacology & Immunocompatibility Pharmacology & Therapeutics

Research

Research Overview

Our research aims to understand the concepts and mechanisms which underly the interface of advanced materials and complex medicines with the immune system; to support their translation to clinical use and gain insight into the fundamental biology behind them. We use advanced techniques and technologies to explore and investigate these areas of research as well as developing new techniques to address gaps in the characterisation knowledge base. To date, we have worked with a wide variety of nanotherapeutics from lipidic nanoparticles to polymeric and from virosomes to exosomes for the delivery of diagnostics, small molecules, biopharmaceuticals, biopolymers and nucleic acids. Our work is supported by funds from bodies including, but not limited to, the European Commission, Wellcome Trust, NIH and Kidney Research UK.

In addition to our academic research, we also offer our services and consulting to developed of nanobiomaterials, advanced therapeutics, and complex medicines. This is via the Nanotherapeutics Hub, based in the Centre of Excellence fof Long-acting Therapeutics (CELT), were we can offer support in areas of immunology (e.g., immune cell responses, mixed lymphocyte reactions, immune cell function), haematology (e.g., haemolysis, comlpement activation, platelet activation, coagulation), and cellular health (e.g., cytotoxicity, cell death pathways, bystander responses to cell death/indirect immune stimulation). Examples of our assay capabilities may be found here

Advanced therapeutics, Biomaterials, and Complex Medicines: assessing their biocompatibility and toxicity.

We utilise complex models (3D, co-culture, new matrices) to unravel the inricate mechanisms underpinning immune responses to advanced therapeutics.
We utilise complex models (3D, co-culture, new matrices) to unravel the inricate mechanisms underpinning immune responses to advanced therapeutics.

Nanomaterial behaviour has been demonstrated to differ considerably from larger bulk material. The production and use of engineered nanomaterials is constantly expanding, but there remain uncertainties surrounding the potential risks posed to human health and environment. The size of nanomaterials influences their toxicity and this has been consistently demonstrated for nanomaterials encountered in workplace environments (e.g. carbon black, polystyrene, titanium dioxide and silver). Nanomaterials vary considerably with respect to their composition, charge, surface area, solubility, crystal structure, surface chemistry and shape.

Many nanomaterials have been shown to interact with the immune system by either stimulating or suppressing various responses through their interaction with proteins found within blood. Many nanomaterials interact with serum proteins such as opsonins (e.g. antibodies, complement) and are rapidly taken up into cells of the mononuclear phagocyte system (e.g. macrophages). Interactions with serum proteins may render nanomaterials antigenic and it has been suggested that functionalisation (e.g. with growth factors, receptors) may induce neutralising antibodies that also recognise the body’s own molecules with implications similar to those for biotechnology-derived therapeutics. We are utilising a number of approaches to understand how nanomaterials interact with biological systems. Identification of these mechanisms may allow rational design of future materials and reduction of unwanted effects; particularly how comlex systems can interact, to bring about clinical events

Interaction of nanomaterials with the human immunological & haematological systems, pathways of cellular uptake of nanoparticles (both receptor and non-receptor mediated), nanotoxicity of nanomaterials and interaction of nanoparticles with plasma proteins (biomolecular corona). immune modulation, hypersensitivity and pseudo allergy related to advanced materials such as liposomes and lipidic nanoparticles, liposomes, polymeric materials, inorganic nanoparticles, virosomes and exosomes and nanobiomaterials.

Keywords: advanced therapies and therapeutics, liposomes, lipidic nanoparticles (LNP), CARPA, pseudoallergy, hypersensitivity, complex medicines, extracellular vesicles, nanomedicines, nanotherapeutics, biocompatibility, immunology, immunotoxicology, intracellular drug delivery (ICD)

Sub-project;

- Development of techniques and technologies for the characterisation of nanomaterials.
The field of nanoimmunotoxicology is constantly evolving as new materials are developed. In order to meet these challenges it is necessary to ensure that current techniques and methodologies are sufficient to identify nanomaterial interactions with biological systems that may be undesirable. New characterisation techniques are studied for their utility and introduced into our assay cascade as appropriate. Interaction with agencies such as EMA and FDA are also key in order to stay ahead of what is required from a regulatory perspective.

Impact of immune status on nanomaterial biocompatibility, drug disposition and intracellular pharmacology.

Colocalisation of CXCR4 (green) and ABCB1 (red) in CD4+ T cells. Interaction between, and upregulation of these proteins can affect response to HIV antiretrovirals. We have shown previously that they are influenced by immune signalling and, colocalised in the cell membrane.
Colocalisation of CXCR4 (green) and ABCB1 (red) in CD4+ T cells. Interaction between, and upregulation of these proteins can affect response to HIV antiretrovirals. We have shown previously that they are influenced by immune signalling and, colocalised in the cell membrane.

Dysregulation of the immune system is a hallmark of a number of diseases such as HIV. The mechanisms by which the immune system can influence drug disposition are relatively understudied but recent work has highlighted the necessity for examining its impact on pharmacokinetics and pharmacodynamics. A more comprehensive approach in clinical studies will allow better determination of the impact of cytokines on drug disposition. In addition, determining the mechanisms that underpin the differential effects of cytokines across different cell types will clarify the responses reported in these studies. This in turn relates to the biocompatibility of nanomaterials in patients with dysregulated immune systems as in HIV infection, specifically when comparing the response of uninfected vs infected cells.

Cytokines etc. are integral to the successful resolution of many diseases. Data are emerging on a role for regulation of the expression, and activity, of drug transporters and drug metabolising enzymes.. Investigation of the interaction between pharmacological and immunological responses is key to understanding the complex relationships involved in patient response to therapy as well as how they may respond to nanoformulated therapies.

Keywords: immune response, drug disposition, human immune cells

Influence of metabolic profile, nutrient sensing and exogenous factors on immune responses to xenobiotics and exogenous materials.

In silico modelling of the interaction of antiretovirals with SLC2A1 (GLUT1). We have shown that ARVs can inhibit immune cell respones, possibly as a result of inhibition of glucose uptake, and alter cell bioenergetics (Heaton et al, 2022 [Biomedicine & Pharmacotherapy]; Henshaw et al, 2022 [unpublished]).
In silico modelling of the interaction of antiretovirals with SLC2A1 (GLUT1). We have shown that ARVs can inhibit immune cell respones, possibly as a result of inhibition of glucose uptake, and alter cell bioenergetics (Heaton et al, 2022 [Biomedicine & Pharmacotherapy]; Henshaw et al, 2022 [unpublished]).

Activation of immune cells, results in alteration of energy and nutrient requirements in order to provide sufficient energy resource for the cells and biomass for replication and protein synthesis. Upon activation, immune cells increase their uptake of glucose in order to power cellular processes by glycolysis. Glucose uptake is, primarily, accomplished by the glucose uptake transporters GLUT1 and GLUT4. We have shown that the antiretroviral drugs Efavirenz and Lopinavir can inhibit the activation of primary immune cells (T cells and monocyte-derivd macrophages); nanoformulations of these drugs appear to mitigate some of these processes. Work from the group has demonstrated that Efavirenz and Lopinavir can inhibit glucose uptake, altering bioenergetic profiles in immune cells.. We are determining the activity of metabolite transporters in the metabolic responses to immunological challenges and assessing the long-term implications of exposure to xenobiotics on metabolic profiles.

Additionally, other factors within the local environment may influence immune cell behaviour. Exosomes are nano-sized, extracellular vesicles that are involved in intercellular communication and are generally thought to be involved in immune homeostasis. Their presence in, multiple, biological fluids suggests their importance in controlling the immune response. We have shown that the presence of so-called “tolerosomes” in the plasma may dampen the immunological response of human immune cells to pro-inflammatory stimuli. The aim of this work is to ascertain further the impact of tolerosomes on immunological responses to stimuli, as well as engineered nanobiomaterials, to further our understanding of interindividual responses to treatments.

Keywords: immune metabolism, microenvironment, transporters

Research Group Membership

Research Grants

A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis (SINPAIN)

UK RESEARCH AND INNOVATION (UKRI) (UK)

May 2022 - October 2026

Safety Testing In The Life Cycle Of Nanotechnology-Enabled Medical Technologies For Health (SAFE-N-MEDTECH)

EUROPEAN COMMISSION

April 2019 - September 2023

Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices (REFINE)

EUROPEAN COMMISSION

December 2017 - February 2022

Assessing the therapeutic effects of renal regenerative medicine therapies using a suite of in vitro assays

CHILDRENS RESEARCH FUND (UK)

February 2021 - October 2021

European Nanotechnology Characterisation Laboratory

EUROPEAN COMMISSION

May 2015 - December 2019

Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease RenalToolBox

EUROPEAN COMMISSION

November 2018 - April 2023

Investigating how cell based regenerative medicine therapies modulate T-cells and macrophages to ameliorate acute kidney injury

KIDNEY RESEARCH UK (UK)

November 2018 - September 2021

Exploring how cell therapies ameliorate renal damage

MERSEY KIDNEY FIRST (UK)

October 2018 - September 2021

Long acting NRTI therapies for HIV

NATIONAL INSTITUTES OF HEALTH (NIH) (USA)

July 2017 - June 2023

Multi-modal high resolution preclinical PET+SPECT+CT scanner

WELLCOME TRUST (UK)

July 2018 - June 2023

Bioengineered substrates for human pluripotent stem cell culture

WELLCOME TRUST (UK)

November 2016 - October 2018

Investigation of the use of nanotechnology to reduce the side effects associated with antiretroviral protease inhibitors

BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY (UK)

May 2015 - December 2016

Characterising the influence of nanoparticle characteristics on their interference/ interaction with endotoxin

ROYAL SOCIETY (CHARITABLE)

October 2015 - September 2016

Research Collaborations

Prof. Yvonne Perie

Project: Structure-activity relationships between liposomes and complement activation
External: University of Strathclyde

Prof . Rongjun Chen

Project: Development of, immunologically silent, PEG-alternatives
External: Imperial College London

Prof. Kirill Afonin

Project: Inflammasome recognition of, and response to, nucleic acid-based nanoparticles
External: UNC Charlotte

Immunocompatibility assessment of, and structural relationships between, nucleic acid nanoparticles.

Dr Rob Vandebriel

Project: Immunotoxicological assessment of nanobiomaterials (REFINE)
External: RIVM - National Institute for Public Health

Dr Sven Even Borgos

Project: Interindividual variability in Immunotoxicological responses to nanobiomaterials
External: SINTEF

Dr Joe Vetro

Project: Immunomodulation of macrohage phenotype using nano-polyplexes
External: University of Nebraska Medical Centre

Dr Joe Vetro

Project: Nucleic acid based nano-therapies for cancer
External: University of Nebraska Medical Centre

Research partnership to develop, biocompatible, nucleic acid based therapies for drug resistant cancers.

Dr Clovis Palmer

Project: Influence of immuometabolism on immune responses in infectious disease
External

Prof. Geir Bjorkoy

Project: Impact of infectious disease on cardiac tissue, mediated by autophagy
External: Norwegian University of Science and Technology (NTNU)

Dr Mohamed Abdel-Mohsen

Project: Influence of glycomic profiles in complement activation
External: The Wistar Institute and Penn Center for AIDS Research

Dr Bryant Nelson

Project: Standardsation of immunotoxicological assessment of nanobiomaterials
External: National Institutes of Health (NIH and ASTM

Prof. Patricia Murray

Project: Assessment of novel model systems to investigate renal inflammation
Internal

Dr Bettina Wilm

Project: Impact of extracellular vesicles on macrophage function and phenotype
Internal

Prof, Rachel Williams

Project: Biocompatibility of advanced materials, with nano-topography
Internal

Dr Tom McDonald

Project: Development of, immunomodulatory, lipidic nanoparticle delivery systems.
Internal